Effects of sequential combined transdermal and oral hormone replacement therapies on serum lipid and lipoproteins in postmenopausal women

被引：28

作者：

Sendag F. ^{[1
]}

Karadadas N. ^{[1
]}

Ozsener S. ^{[1
]}

Bilgin O. ^{[1
]}

机构：

[1] Department of Gynecology, Ege University School of Medicine

来源：

Archives of Gynecology and Obstetrics | 2002年 / 266卷 / 1期

关键词：

Hormone replacement therapy; Lipids; Lipoproteins; Transdermal delivery;

D O I：

10.1007/PL00007497

中图分类号：

学科分类号：

摘要：

The aim of this study was to compare the effects of sequential combined transdermal and oral postmenopausal hormone replacement therapies on serum lipid-lipoprotein profiles risk markers for cardiovascular disease. A prospective randomize study was designed: Ninety-six healthy nonhysterectomised post-menopausal women were randomized to receive either transdermal continuous 17β-estradiol, 0.05 mg/d (Estraderm TTS, Novartis, Basel, Switzerland), with transdermal sequential norethisterone acetate, 0.25 mg/d (Estragest TTS, Novartis, Basel, Switzerland), or oral continuous conjugated equine estrogens, 0.625 mg/d (Premarin 0.625 mg, Wyeth, Philadelphia, U.S.A.), with oral sequential medroxyprogesterone acetate, 10 mg/d (Farlutal 5 mg, Deva, Istanbul, Turkey). 84 women completed the trial, 42 in oral and 42 in the transdermal group. The serum levels of total cholesterol, LDL-cholesterol, HDL-cholesterol, triglycerides, apolipoproteins AI and apolipoproteins B at 6 months after starting treatment were compared with baseline values for both therapies. Both oral and transdermal therapies significantly reduced serum levels of total cholesterol (208-190 mg/dL and 216-199 mg/dL, respectively, p=0.0001) and LDL-cholesterol (128-112 mg/dL and 140-127 mg/dL, respectively, p=0.001). The serum levels of triglycerides did not show any significant change with oral therapy, whereas this lipid fell (128-101 mg/dL, p=0.0001) significantly with transdermal therapy. We found significant decrease in HDL-cholesterol with transdermal therapy while there was no significant change with oral therapy. Apolipoproteins AI, the major protein component of HDL2 subfraction, was increased by oral therapy and lowered by transdermal therapy. As a conclusion, we have found that serum total cholesterol and LDL-cholesterol were lowered by both therapies, with no significant differences between treatments, whereas there were significant differences between treatments according to effects on serum triglycerides and apolipoproteins AI.

引用

页码：38 / 43

页数：5

共 40 条

[1]

Adami S., Rossini M., Zamberlan N., Bertoldo F., Dorizzi R., Lo Cascio V., Long-term effects of transdermal and oral estrogens on serum lipids and lipoproteins in postmenopausal women, Maturitas, 17, pp. 191-196, (1993)

[2]

Austin M., Hokanson J., Edwards K., Hypertriglyceridaemia as a cardiovascular risk factor, Am J Cardiol, 81, (1998)

[3]

Barrett-Connor E., Bush T.L., Estrogen and coronary heart disease in women, JAMA, 265, pp. 1861-1867, (1991)

[4]

Basdevant A., De Lignieres B., Guy-Grand B., Differential lipemic and hormonal response to oral and parenteral 17β estradiol in postmenopausal women, Am J Obstet Gynecol, 147, pp. 77-81, (1983)

[5]

Bush T.L., Miller V.T., Effects of pharmacological agents used during menopause: Impact on lipids and lipoproteins, Menapouse: Physiology and Pharmacology, pp. 187-208, (1987)

[6]

Bush T., Barret-Connor E., Cowan L., Et al., Cardiovascular mortality and non-contraceptive use of estrogen in women: Results from the Lipid Research Clinics Program Follow-Up Study, Circulation, 75, pp. 1102-1109, (1987)

[7]

Chetkowski R.J., Meldrum D.R., Steingold K.A., Randle D., Lu J.K., Eggena P., Hershman J.M., Alkjaersig N.K., Fletcher A.P., Judd H.L., Biologic effects of transdermal estradiol, N Engl J Med, 314, pp. 1615-1620, (1986)

[8]

Cortellaro M., Nencioni T., Boschetti C., Ortolans S., Buzzi F., Et al., Cyclic hormone replacement therapy after the menopause: Transdermal versus oral treatment, Eur J Clin Pharmacol, 47, pp. 555-559, (1991)

[9]

Crook D., Stevenson J.C., Hormone replacement and cardiovascular risk factors, N Engl J Med, 329, pp. 1041-1042, (1993)

[10]

Crook D., Cust M.P., Gangar K.F., Worthington M., Hillard T.C., Stevenson J.C., Whitehead M.I., Wynn V., Comparison of transdermal and oral estrogen-progestin replacement therapy: Effects on serum lipids and lipoproteins, Am J Obstet Gynecol, 166, pp. 950-955, (1992)

← 1 2 3 4 →